




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07D 401/12, 285/24, A61K 31/54, 31/44</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/18762 (43) International Publication Date: 6 April 2000 (06.04.00)</p>
<p>(21) International Application Number: PCT/US99/22160 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: 60/102,021 28 September 1998 (28.09.98) US (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SANDERSON, Philip, E. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). CUTRONA, Kellie [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p style="text-align: right;"><i>late</i></p>
<p>(54) Title: THROMBIN INHIBITORS</p> <p>(57) Abstract</p> <p>Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure (I) or (II) e.g. (III).</p> <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> <div style="text-align: center;">  <p>(III)</p> </div> </div>		

Ref. #22
3202/2 (PHA4160.3)
M. South et al.
09/716,962

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
THROMBIN INHIBITORS

5 BACKGROUND OF THE INVENTION

Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

10 Edwards *et al.*, *J. Amer. Chem. Soc.*, (1992) vol. 114, pp. 1854-63, describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate
15 peptide has been replaced by hydrogen or a substituted carbonyl moiety.

Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

R. J. Brown *et al.*, *J. Med. Chem.*, Vol. 37, pages 1259-1261 (1994)
20 describes orally active, non-peptidic inhibitors of human leukocyte elastase which contain trifluoromethylketone and pyridinone moieties.

H. Mack *et al.*, *J. Enzyme Inhibition*, Vol. 9, pages 73-86 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central core structure.

25

SUMMARY OF THE INVENTION

The invention includes compounds for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal,
30 comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compounds can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.

The invention also includes a compound for preventing or treating
35 unstable angina, refractory angina, myocardial infarction, transient ischemic attacks,


- atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally
- 5 include anticoagulants, antiplatelet agents, and thrombolytic agents.

The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.


10 DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure (formula I or II):

15



or



or a pharmaceutically acceptable salt thereof, wherein

- 20 X is N or CH;

R¹ and R² are independently selected from

- hydrogen,
-phenyl, unsubstituted or substituted with one or more of
C₁₋₄ alkyl,
C₁₋₄ alkoxy,
5 halogen,
hydroxy,
COOH, or
CONH₂,
naphthyl,
10 biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and which
contains from one to four heteroatoms selected from the group consisting
of N, O and S,
15 -C₁₋₇ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
amino,
aryl,
20 C₃₋₇ cycloalkyl,
heteroaryl, or
heterocycloalkyl,
-CF₃
C₃₋₇ cycloalkyl,
25 C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;

or R¹ and R² together with the nitrogen to which they are bound form a 5- or 6-
membered ring containing 1 nitrogen atom;

30





R³ is hydrogen,
-phenyl, unsubstituted or substituted with one or more of
C₁₋₄ alkyl,
C₁₋₄ alkoxy,







- halogen,
hydroxy,
COOH, or
CONH₂,
- 5 naphthyl,
biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and which
contains from one to four heteroatoms selected from the group consisting
10 of N, O and S,
-C₁₋₇ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
amino,
- 15 aryl,
C₃₋₇ cycloalkyl,
heteroaryl, or
heterocycloalkyl,
-CF₃
- 20 C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl; and
- R⁴ is
25 hydrogen,
-C₁₋₄ alkyl,
C₃₋₇ cycloalkyl, or
trifluoromethyl.


In one class of compounds, R¹ is hydrogen; R² is -C₃₋₇ cycloalkyl or -
30 CH₂ C₃₋₇ cycloalkyl; or R¹ and R² form a 5- or 6-membered ring containing 1
nitrogen atom; R³ is hydrogen, aryl, -C₃₋₇ cycloalkyl or -CH₂C₃₋₇ cycloalkyl; and
R⁴ is hydrogen, -C₁₋₄ alkyl, C₃₋₇ cycloalkyl or trifluoromethyl.

Specific examples are shown below in Table 1. Inhibitory activity of compounds of the invention is represented by "*", indicating K_i greater than or equal to 5 nM, or "**", indicating K_i less than 5 nM. Values are as determined according to the in vivo assay described later in the specification.

Table 1







The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. The compounds of the present invention may also have polymorphic crystalline forms, with all polymorphic crystalline forms being included in the present invention.

When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, malcate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.

The term "C₃₋₇cycloalkyl" is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.

The term "C₇₋₁₂ bicyclic alkyl" is intended to include bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1,3-trimethylbicyclo[2.2.1]heptyl (bornyl), and the like. The term "C₁₀₋₁₆ tricyclic alkyl" is intended to include cyclic ring systems having 10-16 carbon atoms arranged in cyclic relationship.

The term "aryl" as used herein except where noted, represents a stable 6- to 10-membered mono- or bicyclic ring system. The aryl ring can be unsubstituted or substituted with one or more of C₁₋₄ lower alkyl; hydroxy; alkoxy; halogen; amino. Examples of "aryl" groups include phenyl and naphthyl.

The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 9- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. Bicyclic unsaturated ring systems include bicyclic ring systems which may be partially unsaturated or fully unsaturated.

Partially unsaturated bicyclic ring systems include, for example, cyclopentenopyridinyl, benzodioxan, methylenedioxyphenyl groups. Especially useful are rings containing one oxygen or sulfur, one to four nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiophenyl, oxazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, tetrazole, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl. Unsaturated heterocyclic rings may also be referred to hereinafter as "heteroaryl" rings.

The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts such as those derived from inorganic acids, e.g. hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate,

maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth
5 metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl;
10 and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Some abbreviations that may appear in this application are as follows.

ABBREVIATIONS

<u>Designation</u>	<u>Protecting Group</u>
BOC (Boc)	t-butyloxycarbonyl
CBZ (Cbz)	benzyloxycarbonyl(carbobenzoxo)
TBS (TBDMS)	t-butyl-dimethylsilyl
<u>Activating Group</u>	
HBT(HOBT or HOBt)	1-hydroxybenzotriazole hydrate
<u>Designation</u>	<u>Coupling Reagent</u>
BOP reagent	benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate
BOP-Cl	bis(2-oxo-3-oxazolidinyl)phosphinic chlorid
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
	<u>Other</u>
(BOC) ₂ O (BOC ₂ O)	di-t-butyl dicarbonate
n-Bu ₄ N ⁺ F ⁻	tetrabutyl ammonium fluoride
nBuLi (n-Buli)	n-butyllithium
DMF	dimethylformamide
Et ₃ N (TEA)	triethylamine
EtOAc	ethyl acetate
TFA	trifluoroacetic acid
DMAP	dimethylaminopyridine
DME	dimethoxyethane
NMM	N-methylmorpholine
DPPA	diphenylphosphoryl azide
THF	tetrahydrofuran
DIPEA	diisopropylethylamine

5

Amino Acid

Ile Isoleucine

Phe	Phenylalanine
Pro	Proline
Ala	Alanine
Val	Valine

IN VITRO ASSAY FOR DETERMINING PROTEINASE INHIBITION

Assays of human α -thrombin and human trypsin were performed by the methods substantially as described in *Thrombosis Research*, Issue No. 70, page 173 (1993) by S.D. Lewis *et al.*

The assays were carried out at 25°C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM CaCl_2 . In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used to measure (at 405 nm) the time dependent appearance of *p*-nitroaniline. sar-PR-pna was used to assay human α -thrombin ($K_m=125 \mu\text{M}$) and bovine trypsin ($K_m=125 \mu\text{M}$). *p*-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of $8270 \text{ cm}^{-1}\text{M}^{-1}$.

In certain studies with potent inhibitors ($K_i < 10 \text{ nM}$) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-GPR-afc ($K_m=27 \mu\text{M}$) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.

Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration $\leq 0.1 K_m$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_o) or presence of inhibitor (V_i) were measured. Assuming competitive inhibition, and that unity is negligible compared $K_m/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for

dissociation of the inhibitor from the enzyme can be obtained from the dependence of V_o/V_i on $[I]$ shown in equation 1.

$$V_o/V_i = 1 + [I]/K_i \quad (1)$$

5

The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized vessels. The compounds of the invention are selective compounds, as evidenced by their inhibitory activity against human trypsin (represented by K_i), which is at least 1000 nM.

15 Thrombin Inhibitors - Therapeutic Uses- Method of Using

Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.

Compounds of the invention are useful for treating or preventing venous thromboembolism (e.g. obstruction or occlusion of a vein by a detached thrombus; obstruction or occlusion of a lung artery by a detached thrombus), cardiogenic thromboembolism (e.g. obstruction or occlusion of the heart by a detached thrombus), arterial thrombosis (e.g. formation of a thrombus within an artery

that may cause infarction of tissue supplied by the artery), atherosclerosis (e.g. arteriosclerosis characterized by irregularly distributed lipid deposits) in mammals, and for lowering the propensity of devices that come into contact with blood to clot blood.

5 Examples of venous thromboembolism which may be treated or prevented with compounds of the invention include obstruction of a vein, obstruction of a lung artery (pulmonary embolism), deep vein thrombosis, thrombosis associated with cancer and cancer chemotherapy, thrombosis inherited with thrombophilic diseases such as Protein C deficiency, Protein S deficiency, antithrombin III
10 deficiency, and Factor V Leiden, and thrombosis resulting from acquired thrombophilic disorders such as systemic lupus erythematosus (inflammatory connective tissue disease). Also with regard to venous thromboembolism, compounds of the invention are useful for maintaining patency of indwelling catheters.

 Examples of cardiogenic thromboembolism which may be treated or
15 prevented with compounds of the invention include thromboembolic stroke (detached thrombus causing neurological affliction related to impaired cerebral blood supply), cardiogenic thromboembolism associated with atrial fibrillation (rapid, irregular twitching of upper heart chamber muscular fibrils), cardiogenic thromboembolism associated with prosthetic heart valves such as mechanical heart valves, and
20 cardiogenic thromboembolism associated with heart disease.

 Examples of arterial thrombosis include unstable angina (severe constrictive pain in chest of coronary origin), myocardial infarction (heart muscle cell death resulting from insufficient blood supply), ischemic heart disease (local anemia due to obstruction (such as by arterial narrowing) of blood supply), reocclusion during
25 or after percutaneous transluminal coronary angioplasty, restenosis after percutaneous transluminal coronary angioplasty, occlusion of coronary artery bypass grafts, and occlusive cerebrovascular disease. Also with regard to arterial thrombosis, compounds of the invention are useful for maintaining patency in arteriovenous cannulas.

30 Examples of atherosclerosis include arteriosclerosis.

 Examples of devices that come into contact with blood include vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

 The thrombin inhibitors of the invention can be administered in such
35 oral forms as tablets, capsules (each of which includes sustained release or timed

release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian

can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 30 mg/kg/day, preferably 0.025-7.5 mg/kg/day, more preferably 0.1-2.5 mg/kg/day, and most preferably 0.1-0.5 mg/kg/day (unless specified otherwise, amounts of active ingredients are on free base basis). For example, an 80 kg patient would receive between about 0.8 mg/day and 2.4 g/day, preferably 2-600 mg/day, more preferably 8-200 mg/day, and most preferably 8-40 mg/kg/day. A suitably prepared medicament for once a day administration would thus contain between 0.8 mg and 2.4 g, preferably between 2 mg and 600 mg, more preferably between 8 mg and 200 mg, and most preferably 8 mg and 40 mg, e.g., 8 mg, 10 mg, 20 mg and 40 mg. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared medicament would contain between 0.4 mg and 4 g, preferably between 1 mg and 300 mg, more preferably between 4 mg and 100 mg, and most preferably 4 mg and 20 mg, e.g., 4 mg, 5 mg, 10 mg and 20 mg.

Intravenously, the patient would receive the active ingredient in quantities sufficient to deliver between 0.025-7.5 mg/kg/day, preferably 0.1-2.5 mg/kg/day, and more preferably 0.1-0.5 mg/kg/day. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, e.g. 0.1 mg/ml, 0.3 mg/ml, and 0.6 mg/ml, and administered in amounts per day of between 0.01 ml/kg patient weight and 10.0 ml/kg patient weight, e.g. 0.1 ml/kg, 0.2 ml/kg, 0.5 ml/kg. In one example, an 80 kg patient, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day. Glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be used as buffers. Consideration should be given to the solubility of the drug in choosing an The choice of appropriate buffer and pH of a formulation, depending on

solubility of the drug to be administered, is readily made by a person having ordinary skill in the art.

The compounds can also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.

The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

Typical uncoated tablet cores suitable for administration of thrombin inhibitors are comprised of, but not limited to, the following amounts of standard ingredients:

Excipient	General Range (%)	Preferred Range (%)	Most Preferred Range (%)
mannitol	10-90	25-75	30-60
microcrystalline cellulose	10-90	25-75	30-60
magnesium stearate	0.1-5.0	0.1-2.5	0.5-1.5

Mannitol, microcrystalline cellulose and magnesium stearate may be substituted with alternative pharmaceutically acceptable excipients.

- 5 The thrombin inhibitors can also be co-administered with suitable anti-platelet agents, including, but not limited to, fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis), anticoagulants such as aspirin, thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various
- 10 vascular pathologies, or lipid lowering agents including antihypercholesterolemics (e.g. HMG CoA reductase inhibitors such as lovastatin or simvastatin, HMG CoA synthase inhibitors, etc.) to treat or prevent atherosclerosis. For example, patients suffering from coronary artery disease, and patients subjected to angioplasty
- 15 procedures, would benefit from coadministration of fibrinogen receptor antagonists and thrombin inhibitors. Also, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter.


- 20 Typical doses of thrombin inhibitors of the invention in combination with other suitable anti-platelet agents, anticoagulation agents, or thrombolytic agents may be the same as those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, or may be substantially less than those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents,
- 25 anticoagulation agents, or thrombolytic agents, depending on a patient's therapeutic needs.





The following synthetic methods can be used to prepare the compounds of the present invention:




METHOD 1

5 As exemplified by Example 3.

Starting 2,4-dihydroxy-3-nitropyridine is reacted with a dehydrating chloride source, for example phosphorous oxychloride, in Step A to give the 4-chloropyridine. This is alkylated in Step B with an acetate equivalent such as ethylbromoacetate. The 4-chloropyridinone is reacted in Step C with 2-
10 mercaptobenzothiazole in the presence of an amine base such as triethylamine, in ethanol. The nitro group is reduced by catalytic hydrogenation over palladium on carbon in ethyl acetate in Step D. The amino group is protected as its bis-BOC derivative using DMAP as a catalyst in Step E and the thioether is oxidised with potassium permanganate in aqueous acetic acid to give the sulfone in Step F. The
15 sulfone is reduced in Step G to the sulfinic acid salt using zinc in ethanolic acetic acid and the sulfinic acid is then reacted with NCS in Step H to give the sulfonyl chloride. In Step I, reaction of the sulfonyl chloride with an amine in the presence of a base such as NMM gives the sulfonamide and the BOC groups are removed in Step J using a strong acid such as anhydrous HCl in ethyl acetate. The ester is then
20 hydrolysed with lithium hydroxide in Step K and the carboxylic acid is coupled to the appropriate amine in Step L to give the final product.









- Amide couplings, e.g., Step L, to form the compounds of this invention can be performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Typically, solution phase amide couplings are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

15

METHOD 2

As exemplified by Example 4.

The product of Method 1, Step L, is reacted with excess formaldehyde and the crude reaction product was hydrolysed in aqueous acid to give the final product.




5

METHOD 3

As exemplified by Example 8.

The product of Method 1, Step K is reacted with excess formaldehyde in Step A and the carboxylic acid then coupled to the appropriate amine in Step B to give the final product.




10







METHOD 4

As exemplified by Example 1.

- 5 The product of Method 1, Step B, is reacted with a 2-mercaptoethanol in Step A. The thioether is then reacted with dehydrating chloride source such as phosphorous pentachloride to give the chloroethyl derivative in Step B. The thioether is then oxidised to the sulfone in Step C using a reagent such as mCPBA or OXONE®, and the nitro group is reduced in Step D by catalytic hydrogenation.
- 10 The amine is then cyclised in Step E by heating a solution of the amine in the presence of a base such as potassium carbonate. The ester is then hydrolysed with lithium hydroxide in Step F and the carboxylic acid is coupled to the appropriate amine in Step G which is then deprotected in Step H using a strong acid to give the final product.






Modifications of this method will allow different R^3 groups contemplated by the broad claim below to be present by the use of the appropriate reagent or the appropriate substituted starting material in the indicated synthetic step. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

The following examples are illustrative of the invention as contemplated by the inventors and should not be construed as being limits on the scope or spirit of the instant invention.

EXAMPLE 1

Preparation of 6-(2-Amino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-
7-methyl-5-oxo-3,4,5,6-tetrahydropyrido-[4,3-b]-1,4-thiazine-1,1-dioxide



Step A: 1-Ethyloxycarbonylmethyl-4-(2-hydroxyethylthio)-
6-methyl-3-nitro-2-pyridinone

2-Mercaptoethanol (0.168 mL, 2.4 mmol) was added to a stirred mixture of 4-chloro-1-ethyloxycarbonylmethyl-6-methyl-3-nitro-2-pyridinone (the product of Example 3, Step B, 549 mg, 2.0 mmol) and triethylamine (0.613 mL, 4.4 mmol) in ethanol (4 mL) and the mixture was heated to reflux for 15 min. The reaction was cooled and evaporated to a solid which was purified by flash column chromatography on silica gel (eluting with ethyl acetate), to give the title compound as a pale yellow crystalline solid:
NMR (CDCl₃); δ 1.31 (t, 3H), 2.05 (br t, 1H), 2.37 (s, 3H), 3.18 (t, 2H), 3.93 (br q, 2H), 4.26 (q, 2H), 4.80 (s, 2H), 6.21 (s, 1H).

Step B: 4-(2-Chloroethylthio)-1-ethyloxycarbonylmethyl-6-methyl-
3-nitro-2-pyridinone

Phosphorus pentachloride (229 mg, 1.1 mmol) was added to a stirred solution of 1-ethyloxycarbonylmethyl-4-(2-hydroxyethylthio)-6-methyl-3-nitro-2-pyridinone (316 mg, 1.0 mmol) in methylene chloride (5 mL). After 15 min the reaction was diluted with methylene chloride and was washed with water, dried (Na₂SO₄) and evaporated to give the title compound as a yellow crystalline solid:
NMR (CDCl₃); δ 1.31 (t, 3H), 2.40 (s, 3H), 3.32 (t, 2H), 3.70 (t, 2H), 4.26 (q, 2H),
10 4.81 (s, 2H), 6.01 (s, 1H).

Step C: 4-(2-Chloroethylsulfonyl)-1-ethyloxycarbonylmethyl-6-methyl-3-nitro-2-pyridinone

A mixture of OXONE® (922 mg, 1.5 mmol) and 4-(2-chloroethylthio)-1-ethyloxycarbonylmethyl-6-methyl-3-nitro-2-pyridinone (168 mg, 0.5 mmol) in 1:1 methanol/water (8 mL) was stirred for 8 days. The reaction was partitioned between ethyl acetate and water, and the organic layer was dried (Na₂SO₄) and evaporated to give the title compound as a solid:
NMR (CDCl₃); δ 1.32 (t, 3H), 2.48 (s, 3H), 3.88 (m, 4H), 4.28 (q, 2H), 4.88 (s,
20 2H), 6.59 (s, 1H).

Step D: 3-Amino-4-(2-chloroethylsulfonyl)-1-ethyloxycarbonylmethyl-6-methyl-2-pyridinone

A mixture of platinum (IV) oxide (24 mg) and 4-(2-chloroethylsulfonyl)-1-ethyloxycarbonylmethyl-6-methyl-3-nitro-2-pyridinone (120 mg, 0.33 mmol) in ethanol (3.0 mL) was stirred under hydrogen for 16 h. The reaction was filtered through celite and evaporated to give the title compound as a glass:
NMR (CDCl₃); δ 1.31 (t, 3H), 2.44 (s, 3H), 3.57 (t, 2H), 3.80 (t, 2H), 4.26 (q, 2H),
30 4.79 (s, 2H), 5.90 (br s, 2H), 6.23 (s, 1H).

Step E: 6-Ethyloxycarbonylmethyl-7-methyl-5-oxo-3,4,5,6-tetrahydropyrido-[4,3-b]-1,4-thiazine-1,1-dioxide

A mixture of potassium carbonate (45 mg) and 3-amino-4-(2-chloroethylsulfonyl)-1-ethyloxycarbonylmethyl-6-methyl-2-pyridinone (120 mg,

0.33 mmol) in dimethyl acetamide (1.0 mL) was stirred at 160 °C for 1 h. The reaction mixture was cooled and partitioned between ethyl acetate and dilute HCl. The organic layer was washed with brine, dried (Na₂SO₄) and evaporated to a semi-solid. The crude product was purified by flash column chromatography on silica gel (70-100% ethyl acetate/hexanes gradient) to give the title compound as a colorless crystalline solid:

NMR (DMSO-d₆); δ 1.21 (t, 3H), 2.21 (s, 3H), 3.36 (m, 2H), 3.74 (m, 2H), 4.16 (q, 2H), 4.79 (s, 2H), 6.28 (s, 1H), 6.97 (br s, 1H).

10 Steps F-H: 6-(2-Amino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-7-methyl-5-oxo-3,4,5,6-tetrahydropyrido-[4,3-b]-1,4-thiazine-1,1-dioxide


A mixture of lithium hydroxide monohydrate (21 mg) and 6-ethyloxycarbonylmethyl-7-methyl-5-oxo-3,4,5,6-tetrahydropyrido-[4,3-b]-1,4-thiazine-1,1-dioxide (25.3 mg, 0.084 mmol) in 1:1:1 methanol/THF/water (1.5 mL) was stirred for 64 h. 1M HCl solution (1 mL) was added and the solution was evaporated in vacuo to a solid. EDC.HCl (20.9 mg, 0.109 mmol) was added to a stirred solution of this material, HOBT (14.7 mg, 0.109 mmol), 5-aminomethyl-2-t-butoxycarbonylamino-6-methylpyridine) (20.0 mg, 0.084 mmol) and NMM (0.0212 mL, 0.193 mmol) in DMF (0.4 mL). After 16 h, the reaction was partitioned between ethyl acetate and water. The organic layer was washed with dilute citric acid solution and brine, dried (Na₂SO₄) and evaporated to a glass. The crude product was purified by flash column chromatography on silica gel (0-10% ethanol/ethyl acetate gradient) to give a glass. HCl gas was bubbled through a stirred mixture of this material and ethyl acetate (5 mL) for 15 min at 0 °C. After a further 1 h at rt, the mixture was degassed with nitrogen for 10 min then was filtered through a cotton wool plug, washing with ethyl acetate. The solids were dissolved in methanol and evaporated to a tan solid. This was heated to reflux as a suspension in ethyl acetate (2 mL), cooled and collected by filtration to give the hydrochloride salt of the title compound as a tan solid;

30 NMR (D₂O); δ 2.16 (s, 3H), 2.33 (s, 3H), 3.43 (m, 2H), 3.86 (m, 2H), 4.23 (s, 2H), 6.41 (s, 1H), 6.64 (d, 1H) 7.58 (d, 1H).

EXAMPLE 2

35

Preparation of 6-(2-Amino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-
7-methyl-5-oxo-2[RS]-phenyl-3,4,5,6-tetrahydropyrido-[4,3-b]-1,4-thiazine-1,1-
dioxide




5

The TFA salt of the title compound was prepared from [RS]-1-phenyl-2-
mercaptoethanol using the procedures of Example 1, Steps A-F followed by
hydrolysis and coupling to 2-amino-5-aminomethyl-6-methylpyridine bis HCl salt
10 using the procedure of Example 3, Steps K and L followed by purification by
preparative HPLC (acetonitrile/0.1% aqueous TFA gradient), as a glass;
HRMS (FAB) $C_{23}H_{26}N_5O_4S$ calcd. 468.1706 (M+1)⁺. Found: 468.1709.

EXAMPLE 3

Preparation of 3-amino-1-(2-amino-6-methyl-5-methylenecarbox-
amidomethylpyridinyl)-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone

5

Step A: 4-Chloro-2-hydroxy-3-nitropyridine

Phosphorous oxychloride (63.4 mL, 0.68 mol) was added dropwise
10 to a stirred mixture of 2,4-dihydroxy-3-nitropyridine (28.92 g, 0.17 mol) and
benzyl triethylammonium chloride (155 g, 0.68 mol) in acetonitrile (560 mL).
The reaction mixture was warmed to 60 °C for 1 h then was heated to reflux for 1
h. The reaction was cooled and the volatiles were evaporated in vacuo. An
ice/water slurry (500 mL) was added to the residual oil and the mixture was stirred
15 for 3 h at 0 °C. The solids were collected by filtration, washing with water and
hexanes to give the title compound as a solid;
NMR (CD₃OD); δ 2.33 (s, 3H), 6.39 (s, 1H).

Step B: 4-Chloro-1-ethyloxycarbonylmethyl-3-nitro-2-pyridinone

20 Sodium hydride (60% dispersion in mineral oil, 7.5 g, 0.188 mol)
was added to a stirred solution of 4-chloro-2-hydroxy-3-nitropyridine (23.68 g,
0.126 mol) in THF (250 mL) at 0 °C. After 25 min ethyl bromoacetate (16.7 mL,
0.151 mol) was added and the reaction was warmed to 60 °C. After 20 h the
reaction was cooled and washed with brine acidified with 1M HCl. The organic
25 layer was dried (Na₂SO₄) and evaporated in vacuo to a solid which was
recrystallised from ethyl acetate/hexanes to give the title compound;
NMR (CD₃OD); δ 1.29 (t, 3H), 2.43 (s, 3H), 4.25 (q, 2H), 4.92 (s, 2H), 6.57 (s,
1H).

Step C: 4-(2-Benzothiazinylmercaptyl)-1-ethyloxycarbonylmethyl-3-nitro-2-pyridinone

Triethylamine (10.38 mL, 74.5 mmol) was added to a stirred solution of 4-chloro-1-ethyloxycarbonylmethyl-3-nitro-2-pyridinone (9.3 g, 33.86 mmol) and 2-mercaptobenzothiazole (6.23 g, 37.25 mmol) in ethanol (200 mL) and the reaction was heated to reflux. After 15 min the reaction was cooled and the volatiles were evaporated in vacuo. The residue was partitioned between chloroform and 1M HCl solution. The organic layer was dried (Na₂SO₄) and evaporated in vacuo to a solid which was triturated with 1:1 methanol/hexanes to give the title compound as a pale yellow solid;

NMR (CDCl₃); δ 1.30 (t, 3H), 2.22 (s, 3H), 4.25 (q, 2H), 4.79 (s, 2H), 5.99 (s, 1H), 7.55 (m, 2H), 7.95 (d, 1H), 8.16 (d, 1H).

Step D: 3-Amino-4-(2-benzothiazinylmercaptyl)-1-ethyloxycarbonylmethyl-2-pyridinone

A mixture of 4-(2-benzothiazinylmercaptyl)-1-ethyloxycarbonylmethyl-3-nitro-2-pyridinone (12.5 g, 30.83 mmol) and 10% palladium on carbon (6.25 g) was stirred as a suspension in ethyl acetate (400 mL) under hydrogen. After 16 h, the mixture was filtered through celite and evaporated in vacuo to give the title compound as a solid;

NMR (CDCl₃); δ 1.33 (t, 3H), 2.25 (s, 3H), 4.28 (q, 2H), 4.85 (s, 2H), 4.98 (br s, 2H), 6.24 (s, 1H), 7.30 (t, 1H), 7.42 (t, 1H), 7.70 (d, 1H), 7.89 (d, 1H).

Step E: 4-(2-Benzothiazinylmercaptyl)-3-(N,N-Di-*t*-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone

DMAP (3.1 g, 25.35 mmol) was added to a stirred solution of 3-amino-1-ethyloxycarbonylmethyl-4-(2-benzothiazinylmercaptyl)-2-pyridinone (8.66 g, 23.05 mmol) and di-*t*-butyldicarbonate (17.6 g, 80.66 mmol) in methylene chloride (60 mL). After 16 h, more di-*t*-butyldicarbonate (5.03 g) was added and the reaction was stirred for a further 3 h. The reaction was diluted with methylene chloride and was washed with 10% citric acid solution, dried (Na₂SO₄) and evaporated in vacuo. The residue was triturated with hot ethyl acetate/hexanes to give the title compound as a solid;

NMR (CDCl₃); d 1.29 (t, 3H), 1.47 (s, 18H), 2.21 (s, 3H), 4.23 (q, 2H), 4.78 (s, 2H), 6.10 (s, 1H), 7.44 (t, 1H), 7.53 (t, 1H), 7.84 (d, 1H), 8.07 (d, 1H).

Step F: 4-(2-benzothiazinylsulfonyl)-3-(N,N-di-t-
pyridinone

5 A solution of potassium permanganate (10.6 g, 67.31 mmol) in water (90 mL) was added to a stirred solution of 4-(2-benzothiazinylmercaptyl)-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone (9.686 g, 16.83 mmol) in 4:1 acetic acid/water (250 mL). After 62 h, the reaction was
10 partitioned between ethyl acetate and 10% sodium sulfite solution. The organic layer was washed with 10% sodium sulfite solution, water (2x), sodium hydrogen carbonate solution (2x), water and brine, dried (Na₂SO₄) and evaporated in vacuo to a solid. This was triturated with ether to give the title compound as a solid;
15 NMR (CDCl₃); d 1.15 (s, 18H), 1.28 (t, 3H), 2.45 (s, 3H), 4.21 (q, 2H), 4.79 (s, 2H), 6.94 (s, 1H), 7.60 (m, 2H), 8.01 (d, 1H), 8.21 (d, 1H).

Steps G,H: 4-Chlorosulfonyl-3-(N,N-di-t-butoxycarbonylamino)-1-
ethyloxycarbonylmethyl-2-pyridinone

20 Zinc powder (6.93 g, 106 mmol) was added to a stirred mixture of 4-(2-benzothiazinylsulfonyl)-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone (3.94 g, 6.48 mmol) and acetic acid (8.73 mL) in ethanol (63 mL). After 16 h, the reaction mixture was filtered and evaporated in vacuo at rt. NCS (0.952 g, 7.13 mmol) was added to a stirred
25 mixture of this residue in methylene chloride (100 mL) at -5 °C. After 15 min the reaction was warmed to rt and after a further 40 min the reaction was filtered through celite and evaporated in vacuo to give the title compound contaminated with benzothiazole (1 equivalent) as a yellow solid;
30 NMR (CDCl₃); d 1.31 (t, 3H), 1.44 (s, 18H), 2.42 (s, 3H), 4.26 (q, 2H), 4.83 (s, 2H), 6.57 (s, 1H).

Steps I,J: 3-Amino-4-(N-cyclobutylmethylsulfamoyl)-1-
ethoxycarbonylmethyl-2-pyridinone

NMM (1.43 mL, 13.0 mmol) was added to a stirred mixture of 4-chlorosulfonyl-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone (as a mixture from Step H, 0.84 g) and cyclobutylmethylamine hydrochloride (348 mg, 2.86 mmol) in methylene chloride (15 mL). After 16 h the reaction was diluted with methylene chloride and washed with 10% citric acid solution. The organic layer was dried (Na_2SO_4) and evaporated. The residue was purified by flash column chromatography on silica (40% ethyl acetate/hexanes). HCl gas was bubbled through a stirred solution of the resulting compound in ethyl acetate (10 mL) at 0 °C for 15 min. The reaction was warmed to rt and after a further 3 h it was evaporated to give the title compound as a solid; NMR (CDCl_3); δ 1.30 (t, 3H), 1.64 (m, 2H), 1.88 (m, 2H), 2.04 (m, 2H), 2.24 (s, 3H), 2.44 (m, 1H), 2.99 (t, 2H), 4.25 (q, 2H), 4.68 (br t, 1H), 4.79 (s, 2H), 6.26 (s, 1H).

Step K: 3-Amino-1-carboxymethyl-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone

Lithium hydroxide hydrate (40 mg, 0.952 mmol) was added to a stirred solution of 3-amino-4-(N-cyclobutylmethylsulfamoyl)-1-ethoxycarbonylmethyl-2-pyridinone (170 mg, 0.476 mmol) in 1:3:3 water/methanol/THF (14 mL). After 2 h, the reaction was acidified with 1M HCl and the mixture was partitioned between chloroform and brine. The organic layer was dried (Na_2SO_4) and evaporated to give the title compound as a solid; NMR ($\text{DMSO}-d_6$); δ 1.59 (m, 2H), 1.73 (m, 2H), 1.90 (m, 2H), 2.17 (s, 3H), 2.34 (m, 1H), 2.77 (t, 2H), 4.71 (s, 2H), 5.93 (s, 2H), 6.16 (s, 1H), 7.68 (br t, 2H).


Step L: 3-Amino-1-(2-amino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone

EDC.HCl (85 mg, 0.444 mmol) was added to a stirred solution of 3-amino-1-carboxymethyl-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone (121.9 mg, 0.37 mmol), 2-amino-5-aminomethyl-6-methylpyridine dihydrochloride (93 mg, 0.444 mmol), HOBT (60 mg, 0.444 mmol), and NMM (0.24 mL, 2.22 mmol) in DMF (2.5 mL). After 16 h, the reaction was partitioned between ethyl acetate and water. The organic layer was washed with water and brine, dried (Na_2SO_4)

and evaporated to a solid. The crude product was recrystallized from methylene chloride to give the title compound as a pale yellow crystalline solid;
 NMR (DMSO- d_6); δ 1.60 (m, 2H), 1.77 (m, 2H), 1.91 (m, 2H), 2.14 (s, 3H), 2.22 (s, 3H), 2.35 (m, 1H), 2.86 (d, 2H), 4.10 (d, 2H), 4.65 (s, 2H), 5.72 (s, 2H), 5.90 (s, 2H), 6.13 (s, 1H), 6.22 (d, 1H), 7.19 (d, 1H), 7.65 (br t, 2H), 8.43 (br t, 1H).
 HRMS (FAB) $C_{20}H_{29}N_6O_4S$ calcd. 449.1966 ($M+1$)⁺. Found: 449.1975.

EXAMPLE 4

- 10 Preparation of 6-(2-Amino-6-methyl-5-methylenecarbox-amidomethylpyridinyl)-7-methyl-5-oxo-2-cyclobutylmethyl-3,4,5,6-tetrahydropyrido-[3,4-e]-1,2,4-thiazine-1,1-dioxide:



15


A stirred suspension of 3-amino-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone (30 mg, 0.067 mmol), 37% aqueous formaldehyde (0.1 mL) and 14.8M ammonium hydroxide (0.018 mL) in 2:1 ethanol/water (1.5 mL) was warmed to reflux. After 6 h the reaction was cooled and water was added to give a precipitate which was collected by filtration, washing with water. The solids were dissolved in warm 1M HCl and the solution was then left to stand at rt. The resulting precipitate was collected by filtration to give the title compound as a crystalline solid;

- 25 NMR (DMSO- d_6); δ 1.66 (m, 2H), 1.81 (m, 2H), 1.99 (m, 2H), 2.16 (s, 3H), 2.42 (s, 3H), 2.86 (d, 2H), 4.14 (d, 2H), 4.65 (s, 2H), 4.75 (s, 2H), 6.25 (s, 1H), 6.79 (d, 1H), 6.98 (br s, 1H), 7.65 (br s, 2H), 7.75 (d, 1H), 8.74 (br t, 1H).
 HRMS (FAB) $C_{21}H_{29}N_6O_4S$ calcd. 461.1966 ($M+1$)⁺. Found: 461.1956.

30

EXAMPLE 5

Preparation of 3-Amino-1-(2-amino-6-methyl-5-methylenecarbox-
amidomethylpyridinyl)-4-(N-cyclobutylsulfamoyl)-2-pyridinone



5


The title compound was prepared from 4-chlorosulfonyl-3-(N,N-di-
t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and
cyclobutylamine using the procedures of Example 3, Steps I-L as a crystalline
solid;

10

HRMS (FAB) $C_{19}H_{27}N_6O_4S$ calcd. 435.1809 ($M+1$)⁺. Found: 435.1802.

EXAMPLE 6

15 Preparation of 6-(2-Amino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-
7-methyl-5-oxo-2-cyclobutyl-3,4,5,6-tetrahydropyrido-[3,4-e]-1,2,4-thiazine-1,1-
dioxide



20

The HCl salt of the title compound was prepared from 3-amino-1-
(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-4-(N-
cyclobutylsulfamoyl)-2-pyridinone using the procedure of Example 4, as a
crystalline solid;


25

HRMS (FAB) $C_{20}H_{27}N_6O_4S$ calcd. 447.1809 ($M+1$)⁺. Found: 447.1803.

EXAMPLE 7

Preparation of 3-amino-1-(2-amino-6-methyl-5-methylenecarbox-
amidomethylpyridinyl)-4-(N-cyclopropylsulfamoyl)-2-pyridinone


5



The title compound was prepared from 4-chlorosulfonyl-3-(N,N-di-
t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and
10 cyclopropylamine using the procedure of Example 3, Steps I-L as a crystalline
solid;
HRMS (FAB) $C_{18}H_{25}N_6O_4S$ calcd. 421.1653 (M+1)⁺. Found: 421.1643.

EXAMPLE 8

15 Preparation of 6-(2-Amino-6-methyl-5-methylenecarbox-amidomethylpyridinyl)-
7-methyl-5-oxo-2-cyclopropyl-3,4,5,6-tetrahydropyrido-[3,4-e]-1,2,4-thiazine-1,1-
dioxide



20

A stirred solution of 3-amino-1-carboxymethyl-4-(N-
cyclopropylsulfamoyl)-2-pyridinone (0.26 mmol, prepared from 4-chlorosulfonyl-
3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and
cyclopropylamine using the procedure of Example 3, Steps I-K), 37% aqueous
25 formaldehyde (0.2 mL) and 14.8M ammonium hydroxide (0.036 mL) in 2:1
ethanol/water (1.5 mL) was warmed to reflux. After 1.5 h the reaction was cooled


and evaporated in vacuo. The residue was partitioned between THF and brine, acidified with HCl and the organic layer was dried (Na_2SO_4) and evaporated to a solid. EDC.HCl (60 mg, 0.312 mmol) was added to a stirred solution of this material, 2-amino-5-aminomethyl-6-methylpyridine dihydrochloride (66 mg, 0.312 mmol), HOBT (42 mg, 0.312 mmol), and NMM (0.17 mL, 1.56 mmol) in DMF (3.0 mL). After 16 h, the reaction was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na_2SO_4) and evaporated to a solid. The crude product was purified by flash column chromatography on silica gel (3-8 % methanol/chloroform gradient) and then triturated with methanol to give the title compound as a crystalline solid;

HRMS (FAB) $\text{C}_{19}\text{H}_{25}\text{N}_6\text{O}_4\text{S}$ calcd. 433.1658 ($\text{M}+1$)⁺. Found: 433.1651.

EXAMPLE 9

Preparation of 3-amino-1-(2-amino-6-methyl-5-methylenecarbox-
amidomethylpyridinyl)-4-pyrrolidinylsulfamoyl-2-pyridinone

5




The HCl salt of the title compound was prepared from 4-chlorosulfonyl-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and cyclopropylamine using the procedure of Example 3, Steps I-L as a crystalline solid;
HRMS (FAB) $C_{19}H_{27}N_6O_4S$ calcd. 435.1815 (M+1)⁺. Found: 435.1817.

10

EXAMPLE 10

15

Preparation of 3-Amino-1-(2-amino-6-methyl-5-methylenecarbox-
amidomethylpyridinyl)-4-(N-cyclopropylmethylsulfamoyl)-2-pyridinone




20

The TFA salt of the title compound was prepared from 4-chlorosulfonyl-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and cyclopropylmethylamine using the procedure of Example 3, Steps I-L followed by preparative HPLC (acetonitrile/0.1% aqueous TFA gradient), as a solid;
HRMS (FAB) $C_{19}H_{27}N_6O_4S$ calcd. 435.1815 (M+1)⁺. Found: 435.1817.

25

EXAMPLE 11

Preparation of 6-(2-Amino-6-methyl-5-methylenecarbox-amidomethylpyridinyl)-
 5 7-methyl-5-oxo-2-cyclopropylmethyl-3,4,5,6-tetrahydropyrido-[3,4-e]-1,2,4-
thiazine-1,1-dioxide:



10 The TFA salt of the title compound was prepared from 4-chlorosulfonyl-3-(N,N-di-t-butoxycarbonylamino)-1-ethyloxycarbonylmethyl-2-pyridinone and cyclopropylmethylamine using the procedure of Example 8, followed by preparative HPLC (acetonitrile/0.1% aqueous TFA gradient), as a solid;
 15 HRMS (FAB) $C_{20}H_{27}N_6O_4S$ calcd. 447.1814 (M+1)⁺. Found: 447.1823.

EXAMPLE 1220 Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the following active compounds are prepared as illustrated below (compositions A-I). Active I is 3-amino-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-4-(N-cyclobutylmethyl-sulfamoyl)-2-pyridinone; Active II is 6-(2-Amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-7-methyl-5-oxo-2-cyclobutylmethyl-3,4,5,6-
 25 tetrahydropyrido-[3,4-e]-1,2,4-thiazine-1,1-dioxide; Active III is 3-Amino-1-(2-amino-6-methyl-5-methylene-carboxamidomethylpyridinyl)-4-(N-cyclobutylsulfamoyl)-2-pyridinone; and Active IV is 3-amino-1-(2-amino-6-methyl-5-methylene-carboxamidomethylpyridinyl)-4-pyrrolidinylsulfamoyl-2-pyridinone.

TABLE FOR DOSES CONTAINING FROM
25-100MG OF THE ACTIVE COMPOUND

5	Component	<u>Amount-mg</u>								
		<u>A</u>	<u>B</u>	<u>C</u>	<u>D</u>	<u>E</u>	<u>F</u>	<u>G</u>	<u>H</u>	<u>I</u>
	Active I	25	50	100	-	-	-	-	-	-
	Active II	-	-	-	25	50	100	-	-	-
10	Active III	-	-	-	-	-	-	25	50	100
	Micro-crystalline									
15	cellulose	37.25	100	200	37.25	100	200	37.25	100	200
	Modified									
	food									
	corn starch	37.25	4.25	8.5	37.25	4.25	8.5	37.25	4.25	8.5
20	Magnesium									
	stearate	0.5	0.75	1.5	0.5	0.75	1.5	0.5	0.75	1.5

25 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

30 EXAMPLE 13

Tablet Preparation

Exemplary compositions 3-amino-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone tablets are shown below:

35

Component	0.25 mg	2 mg	10 mg	50 mg
Active IV	0.500%	1.000%	5.000%	14.29%
mannitol	49.50%	49.25%	47.25%	42.61%
microcrystalline cellulose	49.50%	49.25%	47.25%	42.61%
magnesium stearate	0.500%	0.500%	0.500%	0.500%

2, 10 and 50 mg tablets were film-coated with an aqueous dispersion of hydroxypropyl cellulose, hydroxypropyl methylcellulose and titanium dioxide, providing a nominal weight gain of 2.4%.

5

Tablet preparation via direct compression

Active IV, mannitol and microcrystalline cellulose were sieved through mesh screens of specified size (generally 250 to 750 μ m) and combined in a suitable blender. The mixture was subsequently blended (typically 15 to 30 min) until the drug was uniformly distributed in the resulting dry powder blend. Magnesium stearate was screened and added to the blender, after which a precompression tablet blend was achieved upon additional mixing (typically 2 to 10 min). The precompression tablet blend was then compacted under an applied force, typically ranging from 0.5 to 2.5 metric tons, sufficient to yield tablets of suitable physical strength with acceptable disintegration times (specifications will vary with the size and potency of the compressed tablet). In the case of the 2, 10 and 50 mg potencies, the tablets were dedusted and film-coated with an aqueous dispersion of water-soluble polymers and pigment.

20 Tablet preparation via dry granulation

Alternatively, a dry powder blend is compacted under modest forces and remilled to afford granules of specified particle size. The granules are then mixed with magnesium stearate and tableted as stated above.

25

EXAMPLE 14

Intravenous Formulations

Intravenous formulations of 3-amino-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-4-(N-cyclobutylmethylsulfamoyl)-2-pyridinone were prepared according to general intravenous formulation procedures.

5	<u>Component</u>	<u>Estimated range</u>
	Active IV	0.12 - 0.61 mg
	D-glucuronic acid*	0.5 - 5 mg
10	Mannitol NF	50-53 mg
	Water for injection	q.s. 1.0 mL

1N sodium hydroxide is used to achieve a solution pH in the range of between 3.9-4.1.

Exemplary compositions A-C are as follows:

	<u>Component</u>	<u>A</u>	<u>B</u>	<u>C</u>
20	Active IV	0.61 mg*	0.30**	0.15***
	D-glucuronic acid*	1.94 mg	1.94 mg	1.94 mg
	Mannitol NF	51.2 mg	51.2 mg	51.2 mg
25	1 N Sodium Hydroxide	q.s. pH 4.0	q.s. pH 4.0	q.s. pH 4.0
	Water for injection	q.s. 1.0 mL	q.s. 1.0 mL	q.s. 1.0 mL


30 * 0.50 mg free base; ** 0.25 mg free base; *** 0.12 mg free base

Various other buffer acids, such as L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be substituted for glucuronic acid.


35

WHAT IS CLAIMED IS:

1. A compound having the formula:



or



or a pharmaceutically acceptable salt thereof, wherein

X is N or CH;

R¹ and R² are independently selected from

hydrogen,

-phenyl, unsubstituted or substituted with one or more of

C₁₋₄ alkyl,

C₁₋₄ alkoxy,

halogen,

hydroxy,

COOH, or

CONH₂,

naphthyl,

biphenyl,

a 5- to 7- membered mono- or a 9- to 10-membered bicyclic

heterocyclic ring which can be saturated or unsaturated, and which contains from one to four heteroatoms selected from the group consisting of N, O and S,

-C₁₋₇ alkyl, unsubstituted or substituted with one or more of

- 5 hydroxy,
COOH,
amino,
aryl,
C₃₋₇ cycloalkyl,
10 heteroaryl, or
heterocycloalkyl,
-CF₃
C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
15 C₁₀₋₁₆ tricyclic alkyl;

or R¹ and R² together with the nitrogen to which they are bound form a 5- or 6-membered ring containing 1 nitrogen atom;


- 20 R³ is hydrogen,
-phenyl, unsubstituted or substituted with one or more of
C₁₋₄ alkyl,
C₁₋₄ alkoxy,
halogen,
25 hydroxy,
COOH, or
CONH₂,
naphthyl,
biphenyl,
30 a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and which
contains from one to four heteroatoms selected from the group consisting
of N, O and S,
-C₁₋₇ alkyl, unsubstituted or substituted with one or more of






hydroxy,
 COOH,
 amino,
 aryl,
 5 C₃₋₇ cycloalkyl,
 heteroaryl, or
 heterocycloalkyl,
 -CF₃
 C₃₋₇ cycloalkyl,
 10 C₇₋₁₂ bicyclic alkyl, or
 C₁₀₋₁₆ tricyclic alkyl; and

R⁴ is hydrogen,
 -C₁₋₄ alkyl,
 15 C₃₋₇ cycloalkyl, or
 trifluoromethyl.






2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen; R² is -C₃₋₇ cycloalkyl or -CH₂ C₃₋₇ cycloalkyl; or
 20 R¹ and R² form a 5- or 6-membered ring containing 1 nitrogen atom; R³ is hydrogen, aryl, -C₃₋₇ cycloalkyl or -CH₂ C₃₋₇ cycloalkyl; and R⁴ is hydrogen, -C₁₋₄ alkyl, C₃₋₇ cycloalkyl or trifluoromethyl.

25 3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, selected from the group consisting of





5



5

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

10

5. A method for inhibiting thrombus formation in blood comprising adding to the blood a composition of Claim 4.

6. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.
- 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/22160

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :C07D 401/12, 285/24; A61K 31/54,31/44 US CL :546/256, 261; 544/10; 514/222.8,333,335 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 546/256, 261; 544/10; 514/222.8,333,335 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database CAPLUS on STN (Columbus, OH, USA), No. 129:136100, SANDERSON et al. 'Preparation of aminopyridones as thrombin inhibitors,' abstract, 14 September 1998.	1-6
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 16 NOVEMBER 1999	Date of mailing of the international search report 27 JAN 2000	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JANE FAN Telephone No. (703) 308-0196 <i>Jerry Gray for</i>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/22160

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-6, formula I and formula II, X=N
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/22160

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-6, formula I, drawn to bispyridyl compounds.

Group II, claim(s) 1-6, formula II, X=CH, drawn to tetrahydro-pyrido[4,3b]-1,4-thiazines.

Group III, claim(s) 1-6, formula II, X=N, drawn to tetrahydro-pyrido [3,4-e] 1,2,4-thiazine-1,1-dioxides.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: there is no significant structural element present which links the three groups so as to form a single inventive concept. Group I contains monocyclic bis-pyridines; group II contains bicyclic 1,4-thiazines; group III contains bicyclic 1,2,4 thiazines 1,1-dioxides. Therefore, the three groups do not share the same or a corresponding special technical feature.